TCR2 Therapeutics (TCRR) Stock Forecast, Price & News

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TCR2 Therapeutics in the last year. There are currently 6 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" TCRR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TCRR, but not buy additional shares or sell existing shares.
View TCRR analyst ratings or view top-rated stocks.

8 brokerages have issued 12-month target prices for TCR2 Therapeutics' shares. Their TCRR share price forecasts range from $1.68 to $13.00. On average, they anticipate the company's stock price to reach $4.91 in the next year. This suggests a possible upside of 211.0% from the stock's current price.
View analysts price targets for TCRR or view top-rated stocks among Wall Street analysts.

TCR2 Therapeutics' stock was trading at $0.9988 on January 1st, 2023. Since then, TCRR shares have increased by 58.2% and is now trading at $1.58.
View the best growth stocks for 2023 here.

TCR2 Therapeutics saw a decline in short interest in May. As of May 15th, there was short interest totaling 360,900 shares, a decline of 15.9% from the April 30th total of 429,100 shares. Based on an average daily volume of 602,700 shares, the short-interest ratio is currently 0.6 days. Currently, 1.2% of the shares of the company are sold short.
View TCR2 Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our TCRR earnings forecast.

TCR2 Therapeutics Inc. (NASDAQ:TCRR) announced its quarterly earnings results on Thursday, March, 23rd. The company reported ($1.56) earnings per share for the quarter, missing the consensus estimate of ($0.80) by $0.76.

Harbor Disruptive Innovation ETF holds 18,131 shares of TCRR stock, representing 0.10% of its portfolio.

Based on aggregate information from My MarketBeat watchlists, some companies that other TCR2 Therapeutics investors own include Editas Medicine (EDIT), Gossamer Bio (GOSS), Alector (ALEC), Kaleido Biosciences (KLDO), Precision BioSciences (DTIL), Homology Medicines (FIXX), LogicBio Therapeutics (LOGC), Sorrento Therapeutics (SRNE), Atreca (BCEL) and II-VI (IIVI).

(TCRR) raised $76 million in an IPO on Thursday, February 14th 2019. The company issued 5,000,000 shares at $14.55-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and China Renaissance were co-managers.

TCR2 Therapeutics trades on the NASDAQ under the ticker symbol "TCRR."

TCR2 Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Acadian Asset Management LLC (2.07%), Long Focus Capital Management LLC (1.44%), Renaissance Technologies LLC (1.13%), Citigroup Inc. (0.98%), Long Focus Capital Management LLC (0.91%) and Dimensional Fund Advisors LP (0.44%). Insiders that own company stock include Alfonso Quintas Cardama, Garry E Menzel, Kevin C Tang, Mayur Ian Somaiya, Mpm Asset Management Llc and Robert Hofmeister.
View institutional ownership trends.

Shares of TCRR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TCRR stock can currently be purchased for approximately $1.58.

TCR2 Therapeutics (NASDAQ:TCRR) has a market capitalization of $62.03 million. The company earns $-151,820,000.00 in net income (profit) each year or ($4.20) on an earnings per share basis.

The company employs 137 workers across the globe.

TCR2 Therapeutics' mailing address is 100 BINNEY STREET SUITE 710, CAMBRIDGE MA, 02142. The official website for the company is www.tcr2.com. The company can be reached via phone at (617) 949-5200 or via email at investors@tcr2.com.